PubRank

Jeffrey R Marks

Author PubWeight™ 101.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2005 19.56
2 Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008 4.45
3 Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004 2.49
4 Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005 2.37
5 Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002 2.23
6 The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2006 2.06
7 Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007 1.92
8 Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet 2011 1.90
9 Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 2003 1.76
10 Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 2006 1.74
11 Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 2008 1.73
12 High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005 1.71
13 Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 2004 1.68
14 Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009 1.59
15 Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer 2010 1.53
16 Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat 2009 1.46
17 Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 2008 1.43
18 Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006 1.43
19 Analgesic drug use and risk of ovarian cancer. Epidemiology 2006 1.33
20 Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004 1.29
21 Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One 2010 1.28
22 Prediction and uncertainty in the analysis of gene expression profiles. In Silico Biol 2002 1.27
23 Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005 1.23
24 ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 2008 1.19
25 Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 2011 1.17
26 Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae. Eukaryot Cell 2004 1.16
27 Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009 1.16
28 High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. Nucleic Acids Res 2006 1.16
29 Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol 2006 1.15
30 Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 2009 1.15
31 Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 2012 1.14
32 Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007 1.14
33 Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 2008 1.09
34 Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. J Am Coll Surg 2010 1.09
35 Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. Genes Chromosomes Cancer 2004 1.08
36 Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 2005 1.06
37 The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 2011 1.06
38 Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 2004 1.05
39 A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res 2014 1.04
40 IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 2005 1.04
41 Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res 2009 1.03
42 Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. Gynecol Oncol 2012 1.03
43 Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer 2010 1.02
44 Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res 2009 1.01
45 Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. PLoS One 2009 1.00
46 Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Res 2006 0.99
47 Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2007 0.98
48 Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecol Oncol 2007 0.98
49 Do serum biomarkers really measure breast cancer? BMC Cancer 2009 0.95
50 Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. PLoS One 2008 0.94
51 Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Res 2007 0.92
52 Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Res Treat 2005 0.92
53 Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor. Mol Endocrinol 2011 0.91
54 Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 2013 0.91
55 Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer 2010 0.89
56 Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev 2011 0.89
57 Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc 2007 0.87
58 Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men. J Natl Med Assoc 2009 0.86
59 No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev 2003 0.86
60 Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat 2010 0.85
61 Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010 0.84
62 TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. Mol Cancer Res 2004 0.84
63 Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol 2005 0.83
64 Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J Clin Endocrinol Metab 2010 0.81
65 Refining the role of BRCA1 in combating oxidative stress. Breast Cancer Res 2013 0.81
66 IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer 2009 0.78
67 Oxidatively modified proteins as plasma biomarkers in breast cancer. Cancer Biomark 2013 0.77
68 BRCA2 monoclonal antibodies react with differentiating epithelium. Hybrid Hybridomics 2002 0.75